ACAD
Acadia Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
4.53 / 10
Netural
Analyst sentiment is lukewarm: 25% Strong Buy, 50% Buy, 25% Neutral, and 0% Sell, yielding a historical weighted rating of 1.67—below the market average. Simultaneously, fund-flow analysis shows a good score of 7.39/10 with overall inflow ratios below 0.5, hinting at modest institutional interest. Together, the analyst and fund-flow picture reinforces a wait-and-see approach.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
25%
Buy
50%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-02-03
InstitutionHC Wainwright & Co.
Times predicted2
Historical Win Rate0.0%
What is the market sentiment for ACAD?
- ACAD holds a Bearish analyst rating, with 50% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 4.53/10 (Netural).
